Sacubitril/valsartan in chronic kidney disease, the nephrologist point of view
| Autor: | Vicente Álvarez-Chiva, Yamila Saharaui, Antonio de Santos, Borja Quiroga, David Sapiencia |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Nephrology
Male medicine.medical_specialty Attitude of Health Personnel Renal function Tetrazoles 030204 cardiovascular system & hematology urologic and male genital diseases lcsh:RC870-923 Sacubitril Cohort Studies 03 medical and health sciences Angiotensin Receptor Antagonists 0302 clinical medicine Internal medicine medicine Ventricular Dysfunction Humans 030212 general & internal medicine Renal Insufficiency Chronic Aged Retrospective Studies Aged 80 and over Ejection fraction business.industry Aminobutyrates Biphenyl Compounds Middle Aged medicine.disease lcsh:Diseases of the genitourinary system. Urology Drug Combinations Valsartan Heart failure Cardiology Female business Sacubitril Valsartan medicine.drug Kidney disease |
| Zdroj: | Nefrología (English Edition), Vol 39, Iss 6, Pp 646-652 (2019) |
| ISSN: | 2013-2514 |
| Popis: | Introduction: Sacubitril/valsartan reduces cardiovascular morbidity and mortality in patients with systolic dysfunction (SD). The aim of the present study was to assess the evolution of chronic kidney disease (CKD) patients after initiating sacubitril/valsartan. Methods: We included 66 consecutive CKD patients with SD followed up in outpatient care. Patients had to meet the inclusion criteria of having a New York Heart Association class II to IV, receiving maximum tolerated doses of optimal medical therapy and CKD stages 1–4. At baseline, comorbidities and epidemiological data were collected and low doses of sacubitril/valsartan were initiated. At month 1 and 3, doses of sacubitril/valsartan were increased up to the maximum doses if tolerated. In each visit, renal function and cardiac biomarkers were recorded. All the data were analyzed at the end of follow up (6 months). Results: Of the 66 patients, 42 (63 %) were men, with a mean age of 73 ± 15 years. Mean creatinine at baseline was 1.42 ± 0.5 mg/dl (glomerular filtration rate (GFR) estimated by CKD-EPI was 50 ± 19 ml/min/1.73 m2) and mean left ventricular ejection fraction (LVEF) was 31 ± 9 %. At the end of follow up, LVEF improved from 31 ± 9%–39 ± 15 % (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|